Use of animals for toxicology testing is necessary to ensure patient safety in pharmaceutical development

Regulatory Toxicology and Pharmacology

Volumn 70, Issue 2, 2014, Pages 439-441

  Mangipudy, Raja ^a   Burkhardt, John ^b   Kadambi, Vivek J ^c  

^a BRISTOL MYERS SQUIBB   (United States)

^b ABBVIE INC   (United States)

^c Blueprint Medicines   (United States)

Author keywords

3Rs; DruSafe; In vivo toxicology testing; Predictivity

Indexed keywords

ANIMAL TESTING ALTERNATIVE; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; EXPERIMENTAL ANIMAL WELFARE; HAZARD ASSESSMENT; NONHUMAN; NOTE; PATIENT SAFETY; PROCESS OPTIMIZATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; STUDY DESIGN; TOXICITY TESTING; ANIMAL; DRUG DEVELOPMENT; ETHICS; HUMAN; PROCEDURES;

ANIMALIA;

ANIMAL TESTING ALTERNATIVES; ANIMALS; DRUG DISCOVERY; HUMANS; PATIENT SAFETY; RISK ASSESSMENT; TOXICITY TESTS;

EID: 84907473986     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2014.07.014     Document Type: Note

References (10)

1. Animal research: a balancing act Editorial. Nat. Med. 2013, 19:1191.
2. Bailey J., Thew M., Balls M. An analysis of the use of dogs in predicting human toxicology and drug safety. Altern. Lab. Anim. 2013, 41:335-350.
3. Chapman K.L., Holzgrefe H., Black L.E., Brown M., Chellman G., Copeman C., Couch J., Creton S., Gehen S., Hoberman A., Kinter L.B., Madden S., Mattis C., Stemple H.A., Wilson S. Pharmaceutical toxicology: designing studies to reduce animal use, while maximizing human translation. Regul. Toxicol. Pharmacol. 2013, 66:88-103.
4. Ettlin R.A., Kuroda J., Plassmann S., Prentice D.E. Successful drug development despite adverse preclinical findings. Part 1: processes to address issues and most important findings. J. Toxicol. Pathol. 2010, 23:189-211.
5. Ettlin R.A., Kuroda J., Plassmann S., Hayash M., Prentice D.E. Successful drug development despite adverse preclinical findings. Part 2: examples. J. Toxicol. Pathol. 2010, 23:213-234.
6. Greaves P., Williams A., Eve M. First dose of potential new medicines to humans: how animals help. Nat. Rev. 2004, 3:226-236.
7. Hartung T. Food for Thought-Look back in anger - what clinical studies tell us about preclinical work. Altern. Anim. Exp. 2013, 30:275-291.
8. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berge B., Heller A. Concordance of the toxicity of pharmaceuticals in humans and animals. Regul. Toxicol. Pharmacol. 2000, 32:56-67.
9. Roberts R.A., Kavanagh S.L., Mellor H.R., Pollard C.E., Robinson S., Platz S.J. Reducing attrition in drug development: smart loading preclinical safety assessment. Drug Discov. Today 2014, 19:341-346.
10. Tamaki C., Nagayama T., Hashiba M., Fujiyoshi M., Hizue M., Kodaira H., Nishida M., Suzuki K., Takashima Y., Ogino Y., Yasugi D., Yoneta Y., Hisada S., Ohkura T., Nakamura K. Potentials and limitations of non-clinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan. J. Toxicol. Sci. 2013, 38:581-598.